Taking people in ChinaNo phase

Team-Based Treatment Planning for Older Adults With Lung Cancer

Tests a team-based way of choosing treatment for older adults with lung cancer.

Key facts

Who runs it: West China Hospital
Where: Chengdu, ChinaSee the site
Trial code: NCT07509333
Registry title: MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
Status: Recruiting
People taking part: 2,000 people, planned
Started: 5 Apr 2026
Expected to end: 31 Dec 2035
Type of study: Interventional
Treatments tested: MDT-Based Umbrella Decision-Making Model
Record updated: 3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 60 to 90 with newly diagnosed non-small cell or small cell lung cancer. A team of different specialists plans each person's treatment after a full health check for older adults.

Age: 60 to 90 years
Sex: All sexes can join.
Disease stage: Non-small cell or small cell lung cancer confirmed by tissue or cell tests, clinical stage I-IV. ECOG performance status 0-2. Expected to live at least 3 months.

Main reasons for not taking part

Another active cancer within the last 5 years (with a few exceptions)
Lung cancer not confirmed by tissue or cell tests
Emergency that needs treatment right away, before the baseline checks and team review
Thinking or communication problems with no legal representative or helper available
Taking part in another trial whose treatment plan does not fit this care pathway

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

Age 60 to 90 years
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)
Clinical stage I-IV (according to the 9th edition of the IASLC TNM staging system)
ECOG Performance Status 0-2
Estimated life expectancy ≥ 3 months
Able to tolerate baseline examinations (including CT, MRI, pulmonary function tests) and at least one planned treatment modality (surgery, ablation, SBRT, etc.) as assessed by the investigator
Patients or their legal representatives provide written informed consent and commit to completing the full follow-up schedule (including questionnaires and functional assessments)
Other conditions deemed suitable by the investigator

Who cannot take part

History of another active primary malignancy within the previous 5 years, except adequately treated non-melanoma skin cancer, carcinoma in situ, or another malignancy considered unlikely to affect the study outcomes
Concurrent participation in another interventional study that mandates a treatment strategy incompatible with the CGA-informed MDT care pathway
Lung cancer cannot be confirmed by histologic or cytologic examination
Cognitive or communication impairment that prevents completion of the core study procedures when no legally authorized representative or appropriate proxy assistance is available
Any condition that makes the study-specific assessment procedures unsafe, provided that the reason for exclusion is documented by the investigator
A medical emergency requiring immediate treatment that precludes completion of the baseline study procedures and MDT review before treatment initiation
A contraindication to all clinically acceptable methods required for the core study-specific baseline assessment, with no suitable alternative assessment available

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 60 and 90 years old?

Where in China

West China Hospital，Sichuan UniversityChengdu, ChinaContact: Hu LiaoTaking people

About the trial

What the trial wants to find out

This is a single-center, prospective, single-arm interventional study with historical control, designed to evaluate the clinical value of a multidisciplinary team (MDT)-based decision-making umbrella decision model in elderly patients with lung cancer. A total of 2,000 patients aged 60-90 years with newly diagnosed non-small cell or small cell lung cancer will be enrolled. Each patient will undergo comprehensive geriatric assessment and receive an individualized treatment plan formulated by an MDT comprising thoracic surgeons, geriatricians, oncologists, pulmonologists, rehabilitation therapists, and radiologists. Treatment options include surgery, ablation, stereotactic body radiotherapy (SBRT), neoadjuvant immunochemotherapy, targeted therapy, and best supportive care. The primary outcome is 3-year progression-free survival (PFS). Secondary outcomes include overall survival, objective response rate, quality of life (EORTC QLQ-LC43), incidence of adverse events (CTCAE v5.0), and healthcare economics. Historical controls (2014-2024) will be extracted from hospital records and matched using propensity score matching. The study aims to establish a standardized MDT pathway to improve treatment outcomes and reduce risks in the geriatric lung cancer population.

The group in the trial

MDT GroupTreatment being tested
Participants receive individualized treatment plans formulated by a multidisciplinary team (MDT) based on comprehensive geriatric assessment and tumor characteristics. Treatment options include surgery, ablation, stereotactic body radiotherapy (SBRT), neoadjuvant immunochemotherapy, targeted therapy, and best supportive care. All patients undergo standardized follow-up according to protocol.
Treatment: MDT-Based Umbrella Decision-Making Model